TET2 and acute myeloid leukemia: Well-established poor-risk prognostic variables in AML include older age, secondary disease, and adverse cytogenetics; however, recent analyses have also suggested the value of incorporating gene mutations beyond FLT3, NPM1, and CEBPA (e.g., IDH1and IDH2, ASXL1, MLL, DNMT3A, and TET2) into AML risk classifications [4].